ES2574836T3 - Formulación de liberación prolongada de nevirapina - Google Patents

Formulación de liberación prolongada de nevirapina Download PDF

Info

Publication number: ES2574836T3
Authority: ES; Spain
Prior art keywords: nevirapine; release formulation; prolonged release; hpmc; tablets
Prior art date: 2007-06-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES08756672.5T

Other languages

English (en)

Spanish (es)

Inventor

Michael L. Cappola

Svetlana Sienkiewicz

Glenn Charles Snow

Feng-Jing Chen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Boehringer Ingelheim International GmbH

Original Assignee

Boehringer Ingelheim International GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-08

Filing date

2008-06-04

Publication date

2016-06-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2574836(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-06-04 Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH

2016-06-22 Application granted granted Critical

2016-06-22 Publication of ES2574836T3 publication Critical patent/ES2574836T3/es

Status Active legal-status Critical Current

2028-06-04 Anticipated expiration legal-status Critical

Links

NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 title abstract description 33
229960000689 nevirapine Drugs 0.000 title abstract description 16
239000000203 mixture Substances 0.000 title description 6
238000009472 formulation Methods 0.000 title description 5
230000002035 prolonged effect Effects 0.000 title description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract description 4
235000019359 magnesium stearate Nutrition 0.000 abstract description 2
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 abstract 1
229920003130 hypromellose 2208 Polymers 0.000 abstract 1
229940031707 hypromellose 2208 Drugs 0.000 abstract 1
229960001021 lactose monohydrate Drugs 0.000 abstract 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 10
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 10
239000012729 immediate-release (IR) formulation Substances 0.000 description 6
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
229940098802 viramune Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ES08756672.5T 2007-06-08 2008-06-04 Formulación de liberación prolongada de nevirapina Active ES2574836T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US94276507P	2007-06-08	2007-06-08
US942765P		2007-06-08
PCT/US2008/065705 WO2008154234A2 (en)	2007-06-08	2008-06-04	Extended release formulation of nevirapine

Publications (1)

Publication Number	Publication Date
ES2574836T3 true ES2574836T3 (es)	2016-06-22

Family

ID=39739795

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES08756672.5T Active ES2574836T3 (es)	2007-06-08	2008-06-04	Formulación de liberación prolongada de nevirapina

Country Status (28)

Country	Link
US (1)	US8460704B2 (pt)
EP (1)	EP2155169B1 (pt)
JP (1)	JP5417662B2 (pt)
KR (1)	KR101017862B1 (pt)
CN (1)	CN101784263B (pt)
AR (1)	AR066924A1 (pt)
AU (1)	AU2008262031B2 (pt)
BR (1)	BRPI0811732A2 (pt)
CA (1)	CA2687491C (pt)
CL (1)	CL2008001678A1 (pt)
CO (1)	CO6150128A2 (pt)
DK (1)	DK2155169T3 (pt)
EA (1)	EA018377B1 (pt)
EC (1)	ECSP099561A (pt)
ES (1)	ES2574836T3 (pt)
HU (1)	HUE028598T2 (pt)
IL (1)	IL199924A0 (pt)
MA (1)	MA31430B1 (pt)
MX (1)	MX2009007764A (pt)
NZ (1)	NZ578664A (pt)
PE (2)	PE20131035A1 (pt)
PL (1)	PL2155169T3 (pt)
TN (1)	TN2009000510A1 (pt)
TW (1)	TWI419716B (pt)
UA (1)	UA97971C2 (pt)
UY (1)	UY31128A1 (pt)
WO (1)	WO2008154234A2 (pt)
ZA (1)	ZA200904939B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
US8178495B2 (en)	2008-06-27	2012-05-15	Duke University	Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
DK2155169T3 (en)	2007-06-08	2016-06-13	Boehringer Ingelheim Int	Formulation of nevirapine extended release
EP2714045A1 (en)	2011-05-30	2014-04-09	Cipla Limited	Pharmaceutical antiretroviral composition
CN104023784B (zh) *	2011-08-24	2018-05-25	费斯生物制药公司	供持续释放的活性剂制剂
IN2014MN01907A (pt) *	2012-03-05	2015-07-10	Cipla Ltd
CN104523630B (zh) *	2015-01-22	2017-08-25	山东新时代药业有限公司	一种奈韦拉平片剂
EP3153157A1 (en)	2015-10-09	2017-04-12	Teva Pharmaceutical Works Private Limited Company	Pharmaceutical composition for prolonged release of nevirapine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5366972A (en)	1989-04-20	1994-11-22	Boehringer Ingelheim Pharmaceuticals, Inc.	5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5133974A (en)	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
CA2030056C (en)	1989-11-17	1995-10-17	Karl D. Hargrave	5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection
US5419917A (en) *	1994-02-14	1995-05-30	Andrx Pharmaceuticals, Inc.	Controlled release hydrogel formulation
US6514530B2 (en) *	1997-09-09	2003-02-04	Alza Corporation	Dosage form comprising means for changing drug delivery shape
PT1035834E (pt)	1997-12-05	2002-09-30	Alza Corp	Forma de dosagem osmotica que compreende primeiro e segundo revestimentos
AU765909C (en) *	1998-12-17	2004-09-23	Alza Corporation	Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
PL198797B1 (pl) *	1999-03-31	2008-07-31	Janssen Pharmaceutica Nv	Zastosowanie wstępnie żelowanej skrobi
DE60025837T2 (de) *	1999-09-24	2006-11-02	Janssen Pharmaceutica N.V.	Antivirale feste dispersionen
KR100738276B1 (ko)	1999-12-09	2007-07-12	알자 코포레이션	항바이러스성 약제
US6541014B2 (en) *	2000-10-13	2003-04-01	Advancis Pharmaceutical Corp.	Antiviral product, use and formulation thereof
WO2002092095A1 (en)	2001-05-11	2002-11-21	Boehringer Ingelheim International Gmbh	Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine
US20030050620A1 (en)	2001-09-07	2003-03-13	Isa Odidi	Combinatorial type controlled release drug delivery device
AU2003287666A1 (en)	2002-11-13	2004-06-03	Control Delivery Systems, Inc.	Systemic delivery of antiviral agents
EP1643946A2 (en)	2003-06-20	2006-04-12	Viral Genomix, Inc.	Compositions for and methods for treating hiv
US20070231385A1 (en)	2003-10-01	2007-10-04	Lupin Limited	Controlled Release Pharmaceutical Composition and a Process for Preparing the Same
PL1696822T3 (pl)	2003-11-13	2010-08-31	Psivida Inc	Wstrzykiwane implanty o opóźnionym wydzielaniu mające matrycę rdzenia i powłokę podatne na erozję biologiczną
WO2006024668A1 (en) *	2004-09-02	2006-03-09	Janssen Pharmaceutica N.V.	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
US20110104267A1 (en) *	2005-04-25	2011-05-05	Aurobindo Pharma Limited	Pharmaceutical compositions of antiretrovirals
US20090099154A1 (en)	2005-06-29	2009-04-16	Panacea Biotec Ltd.	Pharmaceutical Sustained Release Compositions and Processes Thereof
WO2007052289A2 (en) *	2005-07-22	2007-05-10	Rubicon Research Pvt Ltd.	Novel dispersible tablet composition
FR2891459B1 (fr)	2005-09-30	2007-12-28	Flamel Technologies Sa	Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
CA2625776A1 (en) *	2005-10-14	2007-04-26	Microdose Technologies, Inc.	Pharmaceutical packaging of an oral dosage combination
DK2155169T3 (en)	2007-06-08	2016-06-13	Boehringer Ingelheim Int	Formulation of nevirapine extended release

2008
- 2008-06-04 DK DK08756672.5T patent/DK2155169T3/en active
- 2008-06-04 CN CN2008800193577A patent/CN101784263B/zh active Active
- 2008-06-04 EA EA200900958A patent/EA018377B1/ru not_active IP Right Cessation
- 2008-06-04 US US12/523,226 patent/US8460704B2/en active Active
- 2008-06-04 BR BRPI0811732-2A2A patent/BRPI0811732A2/pt not_active IP Right Cessation
- 2008-06-04 PL PL08756672.5T patent/PL2155169T3/pl unknown
- 2008-06-04 HU HUE08756672A patent/HUE028598T2/en unknown
- 2008-06-04 ES ES08756672.5T patent/ES2574836T3/es active Active
- 2008-06-04 AU AU2008262031A patent/AU2008262031B2/en not_active Ceased
- 2008-06-04 EP EP08756672.5A patent/EP2155169B1/en not_active Revoked
- 2008-06-04 MX MX2009007764A patent/MX2009007764A/es active IP Right Grant
- 2008-06-04 UA UAA200908230A patent/UA97971C2/ru unknown
- 2008-06-04 JP JP2009552940A patent/JP5417662B2/ja active Active
- 2008-06-04 CA CA2687491A patent/CA2687491C/en active Active
- 2008-06-04 KR KR1020097016610A patent/KR101017862B1/ko active Active
- 2008-06-04 NZ NZ578664A patent/NZ578664A/en not_active IP Right Cessation
- 2008-06-04 WO PCT/US2008/065705 patent/WO2008154234A2/en not_active Ceased
- 2008-06-06 UY UY31128A patent/UY31128A1/es not_active Application Discontinuation
- 2008-06-06 PE PE2013000070A patent/PE20131035A1/es not_active Application Discontinuation
- 2008-06-06 CL CL2008001678A patent/CL2008001678A1/es unknown
- 2008-06-06 AR ARP080102446A patent/AR066924A1/es unknown
- 2008-06-06 PE PE2008000969A patent/PE20090371A1/es not_active Application Discontinuation
- 2008-06-06 TW TW097121294A patent/TWI419716B/zh active
2009
- 2009-07-15 ZA ZA200904939A patent/ZA200904939B/xx unknown
- 2009-07-16 IL IL199924A patent/IL199924A0/en unknown
- 2009-07-21 CO CO09075419A patent/CO6150128A2/es unknown
- 2009-08-05 EC EC2009009561A patent/ECSP099561A/es unknown
- 2009-12-04 TN TNP2009000510A patent/TN2009000510A1/fr unknown
- 2009-12-07 MA MA32400A patent/MA31430B1/fr unknown

Also Published As

Publication number	Publication date
DK2155169T3 (en)	2016-06-13
AU2008262031A1 (en)	2008-12-18
JP5417662B2 (ja)	2014-02-19
IL199924A0 (en)	2010-04-15
MA31430B1 (fr)	2010-06-01
ZA200904939B (en)	2010-04-28
WO2008154234A9 (en)	2009-11-26
WO2008154234A3 (en)	2010-01-21
PE20131035A1 (es)	2013-10-01
US8460704B2 (en)	2013-06-11
CN101784263A (zh)	2010-07-21
US20100278918A1 (en)	2010-11-04
CA2687491A1 (en)	2008-12-18
TN2009000510A1 (en)	2011-03-31
UY31128A1 (es)	2009-01-30
KR20100020447A (ko)	2010-02-22
KR101017862B1 (ko)	2011-03-04
CO6150128A2 (es)	2010-04-20
WO2008154234A2 (en)	2008-12-18
EP2155169B1 (en)	2016-03-23
EP2155169A2 (en)	2010-02-24
ECSP099561A (es)	2009-09-29
CA2687491C (en)	2011-09-20
CL2008001678A1 (es)	2009-09-11
HUE028598T2 (en)	2016-12-28
NZ578664A (en)	2011-11-25
JP2010520891A (ja)	2010-06-17
AU2008262031B2 (en)	2011-08-25
MX2009007764A (es)	2009-09-10
TW200916127A (en)	2009-04-16
UA97971C2 (ru)	2012-04-10
PE20090371A1 (es)	2009-04-24
CN101784263B (zh)	2012-11-07
HK1145806A1 (en)	2011-05-06
EA200900958A1 (ru)	2010-04-30
TWI419716B (zh)	2013-12-21
PL2155169T3 (pl)	2016-09-30
EA018377B1 (ru)	2013-07-30
BRPI0811732A2 (pt)	2014-11-18
AR066924A1 (es)	2009-09-23

Publication	Publication Date	Title
US10888522B2 (en)	2021-01-12	Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
RU2616516C2 (ru)	2017-04-17	Фармацевтическая композиция, содержащая олмесартана медоксомил и розувастатин или его соль
NO20065638L (no)	2007-02-12	Formuleringer med kontrollert frigivelse inneholdende vardenafil
KR20230145525A (ko)	2023-10-17	과다 졸림증을 치료하기 위한 방법 및 조성물
US20240139169A1 (en)	2024-05-02	Methods and compositions for treating agitation
PE20040134A1 (es)	2004-03-06	Forma de dosificacion de una vez al dia de pramipexol
BRPI0614091A2 (pt)	2011-03-09	composição farmacêutica sólida de liberação extendida contendo carbidopa e levodopa
AR084102A1 (es)	2013-04-24	Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidos
TW201311242A (zh)	2013-03-16	藥物
CA2677470A1 (en)	2005-10-20	Methods of treatment using eszopiclone
PE20131035A1 (es)	2013-10-01	Formulacion de nevirapina de liberacion prolongada
KR20150002550A (ko)	2015-01-07	타다라필 및 탐수로신을 함유하는 약학적 캡슐 복합 제제
CA2507851A1 (en)	2004-06-17	Combination of ibuprofen and oxycodone for acute pain relief
RU2704613C2 (ru)	2019-10-30	Фармацевтические препараты с фиксированной комбинацией доз обезболивающего и антиспазматического агентов
ES2508490T3 (es)	2014-10-16	Formulación de trimetazidina con diferentes perfiles de liberación
KR102793974B1 (ko)	2025-04-09	우울증을 치료하기 위한 약제학적 조성물
ES2483126T3 (es)	2014-08-05	Formulaciones de formas de dosificación de neramexano
HRP20251043T1 (hr)	2025-10-24	Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća
CN102727456A (zh)	2012-10-17	难溶性药物口腔崩解片及其制备方法
JP4613031B2 (ja)	2011-01-12	催眠剤組成物
JP2009539776A (ja)	2009-11-19	シクロベンザプリンおよびアセクロフェナクの組み合わせを含んでいる薬学的組成物
RU2011140785A (ru)	2014-04-20	Фармацевтическая композиция для лечения диабета 2 типа
Hardenia et al.	2017	Formulation and optimization of fast dissolving tablets of promethazine theoclate using 32 factorial design
CN101062039B (zh)	2010-05-12	治疗神经系统疾病的药物组合物
KR20160081646A (ko)	2016-07-08	멜라토닌 및 설트랄린을 포함하는 경구용 복합정제